Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $38.00 Average Price Target from Brokerages

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a consensus recommendation of “Moderate Buy” by the five analysts that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $38.00.

Several equities research analysts have weighed in on the stock. Oppenheimer lowered their target price on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday, November 18th. Royal Bank of Canada lowered their price objective on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Friday, November 15th. Finally, HC Wainwright reduced their target price on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a research report on Monday, November 18th.

Inovio Pharmaceuticals Stock Performance

Shares of Inovio Pharmaceuticals stock opened at $1.78 on Thursday. Inovio Pharmaceuticals has a one year low of $1.74 and a one year high of $14.75. The company has a market capitalization of $46.46 million, a PE ratio of -0.51 and a beta of 0.75. The company has a 50-day simple moving average of $4.75 and a two-hundred day simple moving average of $7.00.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in INO. Barclays PLC raised its position in Inovio Pharmaceuticals by 282.6% during the 3rd quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company’s stock worth $197,000 after buying an additional 25,116 shares during the last quarter. Geode Capital Management LLC lifted its position in Inovio Pharmaceuticals by 6.7% during the third quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock valued at $3,594,000 after purchasing an additional 38,833 shares during the period. Wellington Management Group LLP purchased a new stake in Inovio Pharmaceuticals in the third quarter valued at $379,000. State Street Corp grew its position in Inovio Pharmaceuticals by 11.7% during the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock worth $2,836,000 after purchasing an additional 51,414 shares during the period. Finally, Atom Investors LP purchased a new position in shares of Inovio Pharmaceuticals during the 3rd quarter valued at about $103,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.